Asim Abdel-Mageed, DVM, MS, PhD



Professor of Urology
Zimmermann Endowed Professor of Cancer Research, Tulane Cancer Center
Adjunct Professor of Pharmacology
Director, Molecular Oncology Research in Urology
Program Member, Louisiana Cancer Research Consortium
Faculty Member, Graduate Program in Biomedical Sciences

Academic Office – (504) 988-3634
Fax: (504) 988-5059


Dr. Abdel-Mageed received his D.V.M. from the University of Khartoum, Sudan, in 1983. He was a veterinary practitioner and a faculty member of the Department of Medicine, Pharmacology and Toxicology at the University of Khartoum until 1987. Dr. Abdel-Mageed obtained M.S. (1989) and Ph.D. (1993) degrees in molecular physiology/toxicology at Kansas State University before joining Tulane as a postdoctoral fellow in the Department of Pharmacology with Dr. Krishna Agrawal in 1994.

Dr. Abdel-Mageed became a research instructor of pharmacology in 1996, continuing his training in molecular cancer pharmacology. He studied genes associated with breast cancer cell growth and their interaction with nuclear transcription factors to mediate mitogenic responses. In 1997, Dr. Abdel-Mageed joined the faculty as an Assistant Professor in the Department of Urology and adjunct Assistant Professor of Pharmacology. He is founding director of the Molecular Oncology Research Laboratories in the Department of Urology. He has over 30 peer-reviewed publications and has served on several DOD grant review panels.

Dr. Abdel-Mageed’s laboratory primarily focuses on basic research into the cellular and molecular aspects of urologic diseases, with particular attention given to prostate and bladder cancer. The laboratory has a special interest in identifying molecular determinants of prostate cancer progression using in vitro and in vivo experimental approaches.

More recently Dr. Abdel-Mageed laboratory has been conducting Department of Defense and American Cancer Society-funded studies pertaining to isolation and characterization of in vivo differentially expressed genes of prostate cancer as they relate to age, race and tumor grade. Using cutting end technology of laser capture mmicrodissection, suppressive subtractive hybridization, and custom cDNA microarray on fresh prostate specimens his lab was able to isolate and characterize a selective subset of race-, and prostate tumor specific nuclear matrix (NM) genes. One area of interest to Dr. Abdel-Mageed is focused on unraveling the mechanisms of nuclear matrix proteins in prostate cancer progression, with special emphasis on their potential role in the disproportionate incidence and mortality of prostate cancer among African American men. Functional analysis of the differentially expressed NM genes should allow for more in depth understanding of the underlying mechanisms regulating growth and metastasis of prostate cancer in African American men.

Additionally, Dr. Abdel-Mageed’s laboratory is conducting research aimed at targeting “intracrine” production by prostate cancer cells at their sanctuary metastatic bone sites. To this end, one of his studies, recently funded by the DoD, is to assess the efficacy of genetically engineered adipose tissue derived stem cells to eliminate androgen production and action on bone metastatic prostate cancer cells. The ultimate goal is to examine their effectiveness as an adjuvant approach to the mainstay androgen deprivation therapy in a preclinical animal model and a clinical setting.

Achievements and appointments include:

  • Synergistic Idea Award-DOD
  • Featured in “The NIH Common Fund: Research Grantee Success Stories
  • Permanent member, Tumor Microenvironment (TME) Study Section, NIH/NCI – Through 2021